美国Verinata Health www.verinata.com
Verinata Health位于加利福尼亚州的圣卡洛斯市，专攻非侵入性测试早期发现胎儿染色体异常。这是一项前瞻性、带有一定探索性冒险性的的研究，临床验证他们第一个产前产前诊断测试。
2013 年Illumina收购Verinata

 
Verinata is driven by a sole, extraordinary purpose — maternal and fetal health. Our initial focus is to develop and offer non-invasive tests for early identification of fetal chromosomal abnormalities using our proprietary technologies. We aim to reduce the anxiety associated with today’s multi-step process, the unacceptable false-positive rates, the non-specific and sometimes confusing results of current prenatal screening methods, as well as the risk of current invasive procedures. In support of national guidelines recommending first trimester aneuploidy risk assessment, we believe women who desire such an assessment should be offered a single blood draw test with a definitive result. Verinata has completed its blinded pivotal study to clinically validate the sensitivity and specificity of its first prenatal test. The verifi™ prenatal test is a non-invasive assay for the determination of the three primary chromosomal aneuploidies for trisomies 21, 18 and 13.